Raymond James analyst Jayson Bedford lowered the firm’s price target on Merit Medical (MMSI) to $108 from $116 and keeps an Outperform rating on the shares. The weakness in shares following the -8% revision in 2025 EPS guidance is a buying opportunity, the analyst tells investors in a research note. The lower guidance is due to the current tariff policies, but Merit has a line-of-sight into mitigation strategies that should reduce the impact by nearly 50% during 2026, the firm says.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Hold Rating for Merit Medical Systems Amid Tariff Challenges and Limited Upside Potential
- Merit Medical price target lowered to $110 from $111 at Baird
- Merit Medical price target lowered to $106 from $117 at Wells Fargo
- Merit Medical price target lowered to $106 from $112 at Piper Sandler
- Merit Medical Systems: Strong Performance and Growth Potential Amid Tariff Challenges